Mupirocin is a topical antibiotic that works by shutting down bacterial protein production through an unusually specific mechanism: it blocks the enzyme bacteria need to load the amino acid isoleucine onto transfer RNA. That precision gives it strong activity against staphylococci and streptococci, the organisms behind most skin infections, while sparing the body’s own cells because human and bacterial versions of the target enzyme differ enough that mupirocin binds only the bacterial one. Clinically, it fills a niche that few other drugs occupy well, serving as a first-line topical treatment for impetigo and a cornerstone of strategies to clear Staphylococcus aureus from the nose before surgery.
How Mupirocin Works
Mupirocin is actually a mixture of closely related compounds called pseudomonic acids, with pseudomonic acid A making up the bulk of what ends up in a tube of ointment. These are produced naturally by the soil bacterium Pseudomonas fluorescens.1PubMed. Biosynthesis of mupirocin by Pseudomonas fluorescens NCIMB 10586 involves parallel pathways The antibiotic’s target is isoleucyl-tRNA synthetase (IleRS), the enzyme responsible for attaching the amino acid isoleucine to its corresponding transfer RNA molecule.2PubMed Central. Inhibition of Isoleucyl-tRNA Synthetase by the Hybrid Antibiotic Thiomarinol When mupirocin occupies the active site of IleRS, the bacterium can no longer incorporate isoleucine into new proteins. At low concentrations this slows growth (bacteriostatic), and at higher concentrations it kills the bacteria outright (bactericidal).3PubMed. A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against Staphylococcus aureus
This mechanism is distinct from every other antibiotic class in routine clinical use. Most antibiotics target cell-wall construction, ribosomal subunits, DNA replication, or folate metabolism. By going after a different step in protein synthesis altogether, mupirocin avoids cross-resistance with drugs like penicillins, cephalosporins, erythromycin, or fluoroquinolones. A strain of S. aureus resistant to methicillin (MRSA) can still be fully susceptible to mupirocin, which is a big part of why the drug remains so clinically relevant decades after its introduction.
What It Works Against
Mupirocin has strong activity against staphylococci and streptococci, which together account for the vast majority of bacterial skin infections. It also shows meaningful activity against some gram-negative organisms, including Haemophilus influenzae and Neisseria gonorrhoeae, but it performs poorly against most gram-negative bacilli and anaerobes.4PubMed Central. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use In practical terms, this means the drug is well suited for skin and soft-tissue infections where staph and strep dominate, but it would not be a sensible choice for infections driven by E. coli, Pseudomonas aeruginosa, or mixed anaerobic flora.
Its potency against staphylococci is especially noteworthy because it extends to MRSA. A comparative review of topical antibiotics for impetigo found that mupirocin has demonstrated clinical efficacy against MRSA, though the authors recommended bacterial culture when resistance is a concern.5PubMed. A comparative review of current topical antibiotics for impetigo That recommendation hints at an important limitation: mupirocin resistance does exist and has been climbing in some populations, a topic worth its own section below.
Treating Skin Infections
The most straightforward use of mupirocin is as a 2% ointment applied directly to superficial skin infections. In trials, impetigo has been the standout indication. Early comparative studies showed a pathogen eradication rate around 92% with mupirocin ointment versus 58% with an inactive vehicle, and overall favorable clinical outcomes in roughly 91% of mupirocin-treated patients.6PubMed. Topical mupirocin in the treatment of bacterial skin infections A larger open-label trial across general practices treated over 1,300 patients with a range of superficial infections. Applied three times daily for an average of nine days, mupirocin cured about 74% and markedly improved another 23%, with a strong safety profile throughout.7PubMed. Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections–an open multicentre trial
Comprehensive reviews have confirmed that the drug performs best in impetigo and reasonably well in infected wounds, though secondary skin infections (such as eczema with a bacterial overlay) sometimes responded nearly as well to the vehicle alone.8PubMed. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use That finding is a useful reminder that not every infected-looking patch of skin needs an antibiotic; the ointment base itself can promote healing in mild secondary infections.
Nasal Decolonization Before Surgery
One of mupirocin’s most impactful uses has nothing to do with treating an active infection. Many people carry S. aureus harmlessly in their nostrils, but when those carriers undergo surgery, the bacteria can migrate to the surgical wound and cause a deep-seated infection. Applying mupirocin ointment inside the nose for a few days before an operation clears the bacteria and substantially lowers the risk of surgical-site infections. Mupirocin is the best-studied agent for this purpose, with the strongest evidence coming from orthopedic and cardiac surgery.9PubMed. Nasal decolonization: What antimicrobials and antiseptics are most effective before surgery and in the ICU
The landmark trial on this approach screened surgical patients for S. aureus carriage and randomized carriers to mupirocin nasal ointment plus chlorhexidine body wash, or to placebo. The rate of S. aureus infection dropped from about 8% in the placebo group to roughly 3% in the treated group, cutting the infection risk by more than half. The effect was even more dramatic for deep surgical-site infections, where the risk fell by nearly 80%.10PubMed. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus These results have made preoperative nasal mupirocin a routine protocol in many hospitals worldwide, often paired with chlorhexidine skin washing.11Clinical Infectious Diseases. Prevention of Surgical Site Infections: Decontamination With Mupirocin Based on Preoperative Screening for Staphylococcus aureus Carriers or Universal Decontamination?
Decolonization After Hospital Discharge
The decolonization concept has been extended beyond preoperative care. Patients who carry MRSA when they leave a hospital face elevated infection risk in the months that follow. A large randomized trial tested whether sending patients home with nasal mupirocin and chlorhexidine body wash could prevent MRSA infections after discharge. In the decolonization group, the rate of MRSA infection was about 6% versus 9% in the control group, translating to a 30% reduction in the hazard of infection and fewer MRSA-related hospitalizations.12PubMed Central. Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers
A secondary analysis from the same trial looked at how effectively the regimen cleared MRSA from different body sites. At one month after the protocol started, colonization at the nares was reduced by about two-thirds compared with the control group, and meaningful reductions persisted at the throat, underarms, groin, and wounds. Even at six months, colonization rates remained significantly lower across all tested sites in the decolonization group.13Clinical Infectious Diseases. Chlorhexidine and Mupirocin for Clearance of Methicillin-Resistant Staphylococcus aureus Colonization After Hospital Discharge The consistent pairing with chlorhexidine body wash is worth noting: mupirocin handles the nose, where S. aureus preferentially colonizes, while chlorhexidine sweeps skin sites the ointment cannot easily reach.
Why Mupirocin Is Topical Only
Given that mupirocin works against MRSA and has a mechanism unlike any other drug class, the obvious question is why it isn’t used as a systemic antibiotic, taken by mouth or given intravenously. The answer is pharmacokinetic: mupirocin is extremely unstable in the bloodstream. Enzymes in plasma chew it apart so quickly that it has an extremely short half-life and gets converted into inactive metabolites before it can reach an infection site in meaningful concentrations.14PubMed. Design, synthesis, and evaluation of mupirocin prodrugs restoring systemic efficacy against MRSA This rapid degradation restricts its use to topical applications, where the drug sits at high local concentrations directly on the bacteria it needs to kill.15PubMed. Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus infections
Researchers have not given up on the idea of making mupirocin work systemically. Some have explored encapsulating it in liposomes to shield it from plasma enzymes, while others have designed prodrug forms that resist degradation until they reach their target. These approaches remain experimental, but they underscore how valuable mupirocin’s unique mechanism could be if its pharmacokinetic limitations were solved.
How Resistance Develops
Bacteria have found two distinct routes to survive mupirocin exposure. Low-level resistance arises from point mutations in the bacterium’s own housekeeping IleRS gene, which subtly alter the enzyme so that mupirocin no longer fits as snugly in its active site. High-level resistance is more dramatic: the bacterium acquires an entirely separate, resistant version of the IleRS enzyme, typically carried on a plasmid that can be shared between bacterial cells.16Biochemical Society Transactions. Exploring mechanisms of mupirocin resistance and hyper-resistance Low-level resistance can sometimes be overcome by the high local concentrations achieved with topical application, but high-level resistance generally means the drug will fail.
The clinical picture of resistance varies by setting. A study of staphylococcal isolates from children with skin complaints in New York City found that prior mupirocin use was strongly correlated with resistance, with an odds ratio above 26.17PubMed Central. High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population That association reinforces the importance of using mupirocin judiciously: repeated or prolonged courses, particularly in community settings where impetigo recurs often in children, can drive up local resistance rates. Clinicians sometimes recommend obtaining a bacterial culture before prescribing mupirocin for impetigo precisely because resistance is no longer rare in some communities.
Peritoneal Dialysis Catheter Care
Patients who undergo peritoneal dialysis have a catheter that exits through the skin of the abdomen, creating a permanent portal for bacteria. S. aureus is one of the most common culprits in exit-site infections and peritonitis in this population. Applying mupirocin ointment to the catheter exit site as part of routine care has been shown to prevent S. aureus exit-site infections and related peritonitis, though it does not reduce infections caused by Pseudomonas aeruginosa or other gram-negative organisms.18PubMed. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients
An exit-site care protocol combining water avoidance with local mupirocin use was found to substantially reduce both catheter-related infections and peritonitis rates in peritoneal dialysis patients.19PubMed. Reduction of peritoneal dialysis associated infections using a novel exit-site care practice When researchers compared topical mupirocin with chlorhexidine cream at exit sites, mupirocin-treated patients experienced fewer infections, though the difference reached only borderline statistical significance after adjusting for other variables.20PubMed. Comparison of Topical Chlorhexidine and Mupirocin for the Prevention of Exit-Site Infection in Incident Peritoneal Dialysis Patients Many dialysis programs now include daily mupirocin application at the exit site as standard practice, a quiet but meaningful public health intervention.
Safety and Side Effects
Mupirocin is generally well tolerated. The most common complaints are mild local reactions: a slight burning or stinging at the application site, occasional dryness or itching. Serious reactions are rare but documented. Case reports have described allergic contact dermatitis, diffuse hives, and, in isolated instances, more severe hypersensitivity responses including widespread rash and low blood pressure.21Advances in Pharmacology and Therapeutics Journal. Mupirocin–Induced Allergic Contact Dermatitis: A Case Report and a Review of the Literature
One safety concern that clinicians keep in mind involves the ointment base rather than the drug itself. The standard mupirocin ointment uses a polyethylene glycol (PEG) vehicle, and PEG can be absorbed through damaged skin in large enough quantities to cause kidney problems. For this reason, recommendations caution against applying mupirocin ointment to large open wounds, particularly extensive burns. Studies in burn patients have recommended restricting use to burns covering less than 20% of total body surface area and limiting application to five days.22Antimicrobial Agents and Chemotherapy. Efficacy of mupirocin in methicillin-resistant Staphylococcus aureus burn wound infection For nasal use and small skin lesions this is not a practical concern, but it matters in settings like intensive care units where open wounds can be extensive. A calcium-based cream formulation exists for nasal application and avoids the PEG issue entirely.
What Mupirocin Does to the Nasal Microbiome
Applying mupirocin inside the nose does not selectively remove only S. aureus. It wipes out most mupirocin-sensitive bacteria, including S. epidermidis and other commensal species that normally contribute to a healthy nasal ecosystem. A study tracking nasal microbiome changes over six months after decolonization found that mupirocin-sensitive species were virtually eliminated immediately after treatment, while naturally resistant organisms like corynebacteria and Cutibacterium acnes remained abundant and temporarily expanded to fill the vacated space.23PubMed Central. Nasal microbiome disruption and recovery after mupirocin treatment in Staphylococcus aureus carriers and noncarriers
Recovery was uneven. In people who carried S. aureus before treatment, the bacterium typically recolonized the nose within about three months. By contrast, beneficial commensals like Dolosigranulum pigrum and Moraxella nonliquefaciens took roughly six months to return. Even at six months, the overall nasal microbial community had not fully returned to its pre-treatment state in either carriers or non-carriers. A separate study found that statistically significant disruption of nasal and throat bacterial communities was detectable at one week but was no longer apparent at eight weeks, with S. aureus relative abundance dropping from about 8% to 0.3% while S. epidermidis dipped transiently and then recovered.24PubMed Central. Effect of mupirocin for Staphylococcus aureus decolonization on the microbiome of the nose and throat in community and nursing home dwelling adults The practical takeaway is that mupirocin decolonization is not a precision strike. It reshuffles the nasal microbial community for months, and repeated courses could cumulatively shift the ecosystem in ways that are not yet well characterized.
Where Mupirocin Came From
Mupirocin’s origin story has an interesting evolutionary wrinkle. P. fluorescens manufactures the antibiotic using a large cluster of biosynthetic genes that appears to have been acquired from elsewhere, much like the way bacteria pick up antibiotic resistance genes. Genomic analysis has shown that the mupirocin gene cluster sits adjacent to transfer RNA genes in the P. fluorescens genome, and comparative sequencing with related strains that do not produce mupirocin suggests the entire cluster was inserted at that site by recombination, resembling the integration events seen with bacterial viruses and mobile genetic elements.25Cell Chemical Biology. Sequence Analysis of the Mupirocin Biosynthesis Cluster in Pseudomonas fluorescens In other words, P. fluorescens likely borrowed the genetic machinery for mupirocin production from another organism at some point in its evolutionary past, and the drug we use in clinics today is a product of ancient horizontal gene transfer in soil bacteria.
Veterinary Use and the Resistance Spillover Question
Mupirocin is not limited to human medicine. Veterinarians use it topically to treat skin infections and for decolonization of staphylococcal carriers among companion animals.26PubMed. Topical treatment of canine and feline pyoderma Testing of coagulase-positive staphylococci isolated from pets found that, for most strains, the drug concentration achievable at the application site would be sufficient for therapeutic effect, including against multiresistant isolates. However, a small number of MRSA isolates from pets already showed resistance levels that could compromise efficacy.27Journal of Antimicrobial Chemotherapy. In vitro activity of fusidic acid and mupirocin against coagulase-positive staphylococci from pets
The concern here is bidirectional transfer. Pets and their owners share staphylococcal strains, so mupirocin-resistant bacteria selected in a dog or cat can colonize the human household members, and vice versa. As mupirocin use expands in veterinary dermatology, monitoring for resistance in animal isolates becomes increasingly relevant to preserving the drug’s effectiveness in human medicine. This is one of many areas where antibiotic stewardship needs to extend across species lines rather than treating human and animal use as separate problems.